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Summary
The ultimate goal of gene therapy is the replacement of
a defective gene sequence with a corrected version to eliminate
disease for the lifetime of the patient. This challenging task is
not yet accomplished, however signiﬁcant progress is evident.
An initial spate of clinical trials attempting the treatment of
haemophilia with gene transfer primarily resulted in the
demonstration of good safety proﬁles, but without efﬁcacy.
Subsequent reengineering of vector plasmids and delivery
systems resulted in markedly improved outcomes in animal
models of the disease. The most recent clinical trial for the
treatment of haemophilia B with gene transfer showed
transient achievement of efﬁcacy in the highest dose cohort
tested, but also exposed a previously hidden barrier to the
future success of these treatments. The progress and problems
of gene therapies for haemorrhagic disorders will be discussed.
This review will concentrate on approaches in or near clinical
application.
Keywords: haemophilia, gene therapy, vectors, adeno-associ-
ated virus.
Overview of gene therapy
The ambitious objective of gene therapy is to edit a defective
gene sequence in situ to achieve complete reversion of a disease
phenotype for the lifetime of the patient. In spite of recent
successes in site-speciﬁc correction of defective gene sequences,
the focus of most gene therapy strategies to date is on gene
addition rather than gene replacement (Urnov et al, 2005).
This simpliﬁed approach relies on a delivery mechanism to
provide a corrected copy of the defective gene without removal
of the error-containing genomic sequence.
While literally hundreds of animal models of disease can
now be effectively treated by gene transfer, a select few diseases
remain the primary focus of much gene therapy research.
A combination of factors including prevalence of disease,
width of therapeutic window, ability to accommodate the
corrected gene sequence in a gene transfer vector, reliability
and availability of animal models of the disease, and funding
and support from disease-speciﬁc foundations, all contribute
to the overrepresentation of these few diseases.
Haemophilia A and B are among the most extensively
researched diseases in the ﬁeld of gene therapy. Small and
large animal models of both diseases are available for
preclinical testing. Importantly, treatment of the disease can
be quantitatively measured through well-deﬁned coagulation
assays, eliminating a problem that plagues gene therapy efforts
for many other disease entities. Another important aspect of
the treatment of haemophilia by gene transfer is that there is
a relatively low threshold for success. If long-term expression
of the defective coagulation factor at 2–3% of wild-type levels
could be achieved, then a substantial reduction in the clinical
manifestations of the disease would be expected (Herzog et al,
1999; Sarkar et al, 2000). Expression of greater than 30% of
the wild-type level of the defective coagulation factor would
result in a phenotypically normal patient under most
circumstances (Pollak and High, 2001), although higher levels
may be required in the face of haemostatic challenge (Plug
et al, 2006).
Another advantage of haemophilia B in the development of
gene therapy strategies is the relatively small size of F9 cDNA
(1Æ4 kB of coding sequence). This is amenable to insertion
into many different gene transfer vectors and allows the
addition of numerous transcriptional regulatory elements to
both improve and restrict transgene expression in select cell
types. F8 cDNA is much larger than that of F9 (>8 kB), and is
not as readily accommodated in gene transfer vectors. Several
strategies have been employed to overcome this difﬁculty.
A ﬁrst step towards more efﬁcient packaging of F8 cDNA was
deletion of the non-essential B-domain (Toole et al, 1986;
Eaton et al, 1987). A dual-vector approach, in which the Factor
VIII heavy chain and light chain are separately encoded by two
different vector genomes, is another mechanism by which the
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A third technique, one that also employs two vectors,
fragments two halves of a cDNA and tethers them through
the use of a 3¢ splice donor site in vector genome A and a 5¢
splice acceptor site in vector genome B (Yan et al, 2000;
Lai et al, 2005). In the future, improvements in vector
manufacturing may make it possible to package even the
larger F8 cDNA into the smaller gene transfer vectors without
signiﬁcantly compromising yield or homogeneity of vector
preparations (Grieger & Samulski, 2005).
Early clinical trials for gene transfer treatment of
haemophilia
Between 1998 and 2001 ﬁve different Phase I clinical trials were
initiated for the treatment of haemophilia by gene transfer
(Kay et al, 2000; Roth et al, 2001; Manno et al, 2003; Powell
et al, 2003). Several different gene delivery systems were used
in these trials, including a retroviral vector, an adenoviral
vector, two different adeno-associated viral vectors, and a non-
viral gene delivery method. The results from each of these trials
are discussed here with background on each of the vector
delivery systems.
Retroviruses are RNA viruses which use reverse transcrip-
tion to generate a double-stranded DNA intermediate during
replication. Replication-defective retroviral vectors also con-
tain an RNA genome that is reverse transcribed and integrated
into the host genomic DNA. Integration provides the potential
for long-term, persistent gene expression but also increases the
risk of the treatment through the potential for insertional
mutagenesis and/or insertional activation of proximal genes, as
was observed following retroviral transduction of haemato-
poietic cells in a gene therapy trial for X-linked severe
combined immunodeﬁciency (Hacein-Bey-Abina et al,
2003a,b; Fischer et al, 2004). Viral coding sequences are
provided in trans during the manufacture of the vector and
are not present at detectable levels in the vector itself. Many
retroviruses, including murine leukaemia virus, are incapable
of penetrating the nuclear membrane. These retroviruses and
associated derivative viral vectors can only transduce dividing
cells, requiring the natural breakdown of the nuclear mem-
brane that occurs during cell division in order to enter the
nucleus.
Given this limitation, it is not surprising that the most
successful treatment strategies for liver-directed treatment of
haemophilia using retroviral vectors devised strategies to
induce hepatocyte cell division. One example of this was the
use of a partial hepatectomy immediately preceding vector
infusion (Kay et al, 1993). In this way, hepatocytes were
induced to undergo cycling during the time of vector infusion.
This approach only yielded low levels of Factor VIII expression
(<1%), but partial correction for at least 5 months, in a canine
model of haemophilia B. An alternative approach to target
dividing hepatocytes is to infuse retroviral vectors into
neonates, whose hepatocytes are naturally undergoing rapid
cell division. This approach was successfully employed by
VandenDriessche et al (1999) to fully correct Factor VIII
deﬁciency in a murine model of haemophilia A. Using an
identical treatment in 13 neonatal mice, 8/13 mice demon-
strated greater than 50% of wild-type Factor VIII activity by
COAtest (chromogenic Factor VIII activity test) assay.
Long-term follow up revealed no signiﬁcant loss of expression
as long as 15 months after vector treatment. This approach was
successfully extended to the canine model of haemophilia B by
Xu et al (2003), who achieved up to 3Æ5% of normal Factor IX
activity levels following retroviral vector transduction of
neonatal haemophilia B dogs.
Previously conducted preclinical studies led to the initiation
of a phase I clinical trial testing a Moloney murine leukaemia
virus-based retroviral vector encoding B-domain deleted
Factor VIII for the treatment of haemophilia A (Greengard
& Jolly, 1999; Roehl et al, 2000; McCormack et al, 2001; Powell
et al, 2003). Doses ranging from 2Æ7 · 10
7 transducing units
(TU)/kg to 4Æ4 · 10
8 TU/kg were tested. The treatment was
well tolerated by all subjects and replication competent virus
was undetectable in all of the collected samples. Factor VIII
levels above 1% were sporadically detected but did not
correlate with the dose administered. Vector DNA was
detectable in peripheral blood mononuclear cells (PBMCs) in
4/8 subjects that received 2Æ8 · 10
7 TU/kg and 8/8 subjects
that received 9Æ2 · 10
7 TU/kg up to 53 weeks after the
infusion. Overall, the signs of clinical improvement following
vector infusion were modest at best. These ﬁndings were
consistent with animal studies suggesting that efﬁcient retro-
viral transduction of hepatocytes would require higher doses
and some degree of mitotic induction.
Adenoviral vectors have been frequently used in preclinical
gene transfer studies of haemophilia. Advantages of these
double-stranded DNA vectors are high transgene expression
levels and the ability to transduce hepatocytes efﬁciently
in vivo. Frequently, however, expression from early generation
vectors was transient, owing to the immunogenic properties of
the adenoviral vectors themselves. In contrast to other vectors
that are devoid of viral gene sequences, early generation
adenoviral vectors encode many viral proteins in addition to
the transgene; these may contribute to the immunogenicity of
these vectors (Schagen et al, 2004). In mice, the immune
response was not sufﬁcient to ablate the effects of the
treatment and curative levels of Factor VIII or Factor IX
could be achieved and sustained for 3–5 months in murine
models of Haemophilia A and B (Smith et al, 1993; Connelly
et al, 1996; Walter et al, 1996). In contrast, large animal
studies demonstrated that the duration of transgene expression
was signiﬁcantly shorter than that seen in mice and that
hepatotoxicity was correspondingly greater (Kay et al, 1994;
Lozier et al, 1999). In a canine study, a vector dose of
2Æ4 · 10
12 plaque forming units (pfu) infused into three
haemophilia B dogs resulted in transient expression of Factor
IX at supraphysiological levels. These levels rapidly declined,
reaching 1% of normal by 3 weeks after vector infusion and
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same vector in mice resulted in sustained levels of Factor IX
expression at 20% of normal for over 4 months (Kay et al,
1994). Further substantiating these ﬁndings was a non-human
primate study in which an adenovirus vector was used to
deliver a human Factor IX transgene. In this study, a peak of
80% wild-type Factor IX levels was achieved at the highest dose
(1 · 10
11 pfu/kg) followed by a rapid decline to baseline, with
human Factor IX levels undetectable by 3 weeks after vector
infusion (Lozier et al, 1999). Moreover, signiﬁcant hepatotox-
icity was observed. Serum aspartate transaminase (AST) levels
rose above 500 U/ml at both the intermediate dose and the
high dose, and bilirubin levels rose above 85Æ5 lmol/l in the
high dose cohort only (Lozier et al, 1999). Thrombocytopenia
was also observed in the intermediate dose and high dose
cohorts. Thrombocytopenia was subsequently linked to
decreased ﬁbrinogen levels and increased platelet clearance
time believed to result from the hepatotoxicity of the vector
(Lozier et al, 1999; Wolins et al, 2003). Recent work by
Othman et al (2007) showed that activation of platelets occurs
following exposure to adenovirus. Activation is, in turn,
followed by upregulation of P-selectin, which is known to
promote platelet clearance (Othman et al, 2007). They also
identiﬁed a critical role for von Willebrand factor (VWF) in
the induction of thrombocytopenia following adenovirus
infusion. Using a vector dose that results in thrombocytopenia
in wild-type mice (1 · 10
11 pfu), signiﬁcant thrombocytope-
nia was not observed in VWF knockout mice.
Further development of adenoviral vector production
systems allowed complete elimination of viral coding
sequences from the vector. The intent of this manoeuvre
was to minimize the immunogenicity of these vectors. Using
these ‘gutted’ adenoviral vectors, sustained correction of
disease phenotype was observed in haemophilia A mice
infused with 3 · 10
12 vector particles (vp)/kg with no
apparent hepatotoxicity. Non-human primate studies showed
some dose-dependent hepatotoxicity with the threshold
residing between 1Æ4 · 10
12 vp/kg and 4Æ3 · 10
12 vp/kg.
A Phase I clinical trial was initiated to test the safety of an
adenoviral vector encoding human Factor VIII for the
treatment of Haemophilia A; because of a priori concerns
regarding immunogenicity, the trial was structured to mon-
itor carefully for changes in liver function tests or platelet
count. The ﬁrst subject, enrolled at the lowest dose of
4Æ3 · 10
10 vp/kg, experienced inﬂammation, fever and myal-
gia upon vector infusion; these symptoms are commonly
observed with infusion of adenoviral vectors. The subject also
experienced thrombocytopenia and an elevation in serum
transaminases that peaked 7 d after infusion and returned to
baseline by 19 d postinfusion (Chuah et al, 2004). Due to
safety concerns and a perceived narrow therapeutic index, no
additional subjects were enrolled in this trial.
A third vector modality used in this ﬁrst group of clinical
trials was the adeno-associated virus (AAV) vector. AAV is
a small, single-stranded DNA virus that is naturally replica-
tion-defective. It relies on functions of the gene products of
helper viruses, such as adenovirus or herpesvirus, in order to
complete its replication cycle. There are no known symptoms
or diseases associated with AAV infection. The small vector
genome results in a small coding sequence capacity for AAV
vectors, making construction of F9 vectors more straightfor-
ward than construction of those for Factor VIII (although
studies employing AAV vectors for the treatment of animal
models of haemophilia A have been successful). Despite the
fact that the vector DNA remains largely episomal (i.e. without
vector genome integration), AAV vectors can nonetheless
direct long-term expression of a transgene, if introduced into a
long-lived, postmitotic (non-dividing) target cell (Nakai et al,
2001; Song et al, 2004). Early work with AAV vectors for the
treatment of haemophilia B used muscle-targeted vectors
encoding the Factor IX transgene under the control of the
cytomegalovirus (CMV) promoter. With this construct, ther-
apeutic levels of serum Factor IX (200–350 ng/ml) were
achieved in mice (Herzog et al, 1997). Unlike other viral
vectors, transduction of muscle cells with AAV vectors resulted
in sustained expression of the transgene in immunocompetent
mice, even when a foreign transgene such as beta-galactosidase
was used (Xiao et al, 1996; Fisher et al, 1997; Monahan et al,
1998). Muscle-directed AAV vectors were subsequently shown
to achieve low but possibly clinically relevant plasma levels
(70 ng/ml) of canine Factor IX in haemophilia B dogs at a
vector dose of 8Æ5 · 10
12 vp/kg. This level of expression was
sustained for greater than 17 months (Herzog et al, 1999).
In 1999, a Phase I/II clinical trial was initiated to test the
safety and efﬁcacy of intramuscularly delivered AAV vectors
encoding a CMV-driven F9 transgene for the treatment of
haemophilia B. Doses ranged from 2 · 10
11 vector genomes
(vg)/kg to 1Æ8 · 10
12 vg/kg. The vector infusion was well
tolerated in all subjects, with no adverse events related to
vector infusion. No toxicity has been observed in over 7 years
of follow-up after vector administration (Kay et al, 2000;
Manno et al, 2003). Importantly, transgene expression was
evident and sustained. Muscle biopsies taken 2 months,
10 months and >3 years after vector administration revealed
the persistence of vector genomes as determined by Southern
blot as well as local expression of Factor IX protein as shown
by immunoﬂuorescent staining (Manno et al, 2003; Jiang
et al, 2006). This was strong evidence that the animal models
of AAV vector-mediated gene transfer were predictive of the
outcome in humans and that sustained transgene expression
was possible. The barrier to the use of this approach as a
treatment for haemophilia was the number of muscle
injections that would be required in an adult haemophilia
patient. Cell culture and animal studies previously established
a limit to the amount of correctly processed, functionally
active Factor IX protein that could be produced in muscle
cells (Arruda et al, 2001; Herzog et al, 2002). This stipulated a
requirement for a larger number of muscle cells to be
transduced by a larger vector dose, rather than the transduc-
tion of the same number of muscle cells with larger doses of
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vector would be required, and the number of injections
thought to be required to reach a therapeutic effect was
deemed clinically impractical.
In addition to viral vector delivery methods, one non-viral
delivery method was also tested in a clinical trial (Roth et al,
2001). This approach, similar in some respects to previous
clinical studies conducted in China (Lu et al, 1993; Qiu et al,
1996), consisted of transplantation of F8-transduced auto-
logous ﬁbroblasts. After isolation from a skin biopsy, patient
cells were transfected with a plasmid encoding a human F8
cDNA ex vivo and stable selection for transfectants was carried
out. Single clones were expanded and tested for Factor VIII
expression level, as well as tumorigenicity and microbial safety,
prior to reimplantation onto the omentum. Animal model
studies were promising for this approach, but data acquired
from the Phase I clinical trial showed only a modest and
temporary indication of positive effects. The treatment was,
however, well tolerated and leaves open the possibility of
future attempts using more potent expression systems for the
ex vivo transduction and selection process. An important step
in advancing this treatment modality will be the determination
of the cause for the apparent loss of expression over time.
Possible obstacles to durable transgene expression include:
senescence of the implanted cells, promoter inactivation,
ﬁbrosis around the transplanted cells and immune responses
to the gene-modiﬁed cells.
Recent developments in gene transfer for
haemophilia
Adenovirus vectors are still being pursued as a means of
obtaining long-term expression of both Factor VIII and Factor
IX. Improved liver-speciﬁc promoters and further redesign of
production methods resulted in long-term expression of
Factor VIII in canine models of haemophilia A, although
some hepatotoxicity remains evident and could complicate
translation into clinical trials (Andrews et al, 2002; Chuah
et al, 2003; Brown et al, 2004). Speciﬁcally, inter-subject
variation and a small therapeutic index make the safe use of
adenoviral vectors difﬁcult for stable gene transfer in humans.
As a result of their inherent immunogenicity, adenoviral
vectors are now more frequently used as vaccine delivery
vehicles (Tatsis & Ertl, 2004).
New developments in the ﬁeld of retroviral vectors are more
promising for application in the treatment of haematological
disorders. One of the most important innovations has been the
development of lentiviral vectors, which have several advan-
tages over the ﬁrst-generation retroviral vectors. First, they are
capable of transducing non-dividing cells, making them more
suitable for transduction of, for example, hepatocytes and
haematopoietic stem cells. Second, while retroviral vectors
preferentially integrate their genomes near transcriptional start
sites, lentiviral vectors show a random integration pattern into
the open-reading frames of genes (Mitchell et al, 2004). While
this difference does not eliminate the risk of insertional
mutagenesis, it seems likely to mitigate the risk by reducing the
number of full length gene transcripts that might be activated
through vector genome insertion. Improvements in insulator
elements ﬂanking coding sequences within the vector genome
itself further reduced the potential for undesirable insertional
activation events (Chung et al, 1997). Naldini et al showed
that the use of a liver-speciﬁc promoter in place of a CMV
promoter could alone be a determinant of stable lentiviral
transduction of hepatocytes (Follenzi et al, 2004). With
a ubiquitous CMV promoter driving expression of either
green ﬂuorescent protein (GFP) or human Factor IX, expres-
sion was short-lived and the loss of expression was accompa-
nied by both antibody formation against the transgene and
T cell inﬁltrates in the liver. In contrast, use of a liver-speciﬁc
promoter resulted in long-term, stable expression of GFP or
human Factor IX in wild-type mice with expression levels of
the latter reaching 200 ng/ml. In a subsequent study, Naldini
et al also showed that the incorporation of four copies of
a microRNA target sequence in the vector genome could
selectively mark vector transcripts for destruction in cells
expressing the corresponding microRNA (Brown et al, 2006).
Using this lineage-speciﬁc suppression strategy, selective
downregulation of transgene expression in haematopoietic
cells was achieved. This vector demonstrated decreased
immunogenicity and more robust, stable transgene expression
in immunocompetent mice.
Silencing elements encoded by a lentiviral vector transcript
were also used to demonstrate therapeutic effect in a recent
study of lentiviral-mediated gene transfer for the treatment of
sickle-cell disease. Unlike many other genetic disorders, sickle
cell disease cannot be completely corrected by the addition of
a wild-type copy of the defective gene. The mutant globin
would act as a dominant negative gene product and suppress
the activity of the wild-type therapeutic globin. Similar to the
approach taken by Brown et al (2006), Samakoglu et al (2006)
developed a small interfering RNA (siRNA) element targeting
sickle-globin RNA that was inactive against the vector-encoded
therapeutic gamma-globin transgene RNA. The siRNA was
incorporated into an intron within the gamma-globin trans-
gene. Following transcription of the transgene, both expression
of the therapeutic gamma-globin and post-transcriptional
downregulation of the beta-globin (sickle) RNA levels were
observed. This experiment was conducted in haematopoietic
cells taken from human patients with sickle cell disease, and
provides proof-of-principle that this approach could be
translated into the clinic. Chang et al (2006) recently demon-
strated the potential for lentiviral transduction of haemato-
poietic stem cells for the production of Factor IX for the
treatment of haemophilia B.
Continued advances were also made in animal models of
AAV vector-mediated gene transfer for treatment of haemo-
philia. Substantial improvements in transgene expression levels
were made through the use of liver-speciﬁc promoters and
portal vein administration. Therapeutic levels of human Factor
Review
ª 2008 The Authors
482 Journal Compilation ª 2008 Blackwell Publishing Ltd, British Journal of Haematology, 140, 479–487IX could be expressed and sustained in mice, dogs and non-
human primates (Snyder et al, 1997; Wang et al, 1999; Mount
et al, 2002; Nathwani et al, 2002). In wild-type mice, supra-
physiological levels of 6Æ25 lg/ml were attained in haemophilia
B mice from an AAV dose of 5Æ6 · 10
11 vg/mouse
(2 · 10
13 vg/kg) (Wang et al, 1999). These levels were
sustained without any apparent signs of diminution for over
20 weeks. Importantly, these results were scalable to larger
animal models. Haemophilia B canines treated with a vector
dose of 1–2 · 10
12 vg/kg responded with expression of circu-
lating canine Factor IX between 220 ng/ml and 590 ng/ml (4–
12%) (Mount et al, 2002). Non-human primates infused
through the portal vein with an AAV vector dose of
4 · 10
12 vg/kg achieved human Factor IX levels of greater
than 400 ng/ml (8%) which were sustained for more than
1 year (Nathwani et al, 2002). None of these studies reported
liver toxicities or abnormalities in serum chemistries.
Further excitement was generated by the discovery of new
AAV serotypes that were isolated from non-human primate
tissues by polymerase chain reaction, using primers designed
within known conserved sequences from previously identiﬁed
AAVs (Gao et al, 2002). These new serotypes possessed several
advantages over the more extensively studied, prototypical
human-derived AAV2 serotype. AAV vectors are highly
sensitive to antibody-mediated neutralization in vivo (Scallan
et al, 2006). The frequency of antibodies to these novel AAV
serotypes in the human population was greatly reduced
compared to the frequency of the population carrying
antibodies to the human derived strains of AAV (Gao et al,
2002; Scallan et al, 2006). This would mean the exclusion of
fewer patients should a treatment ultimately be developed.
Another advantage of the new serotypes is that, unlike AAV2
which must be delivered directly into the portal vein to achieve
maximal liver transduction, the novel AAV8 serotype demon-
strates equally efﬁcient transduction of the liver in animals
whether infused directly into the portal vein or into a periph-
eral vein. This ﬁnding was initially documented in mice and
has been conﬁrmed in subsequent non-human primate studies
(Sarkar et al, 2004; Davidoff et al, 2005; Nakai et al, 2005).
This provides a less invasive delivery method for clinical
application. Yet another advantage seen with the novel AAV8
serotypes was far superior transduction efﬁciency in the liver,
resulting in 10–100· greater transgene expression in mice (Gao
et al, 2002; Nakai et al, 2005). In contrast to the scalability of
route of administration, however, this ﬁnding did not ascend
the evolutionary ladder. Non-human primate studies directly
comparing multiple serotypes showed an attenuated advantage
of the novel serotypes over other serotypes in stable transduc-
tion of hepatocytes (Davidoff et al, 2005; Gao et al, 2006). To
date, neither AAV2 nor any of the novel serotypes have
exhibited any immunogenicity or hepatotoxicity in animals,
either at the time of administration or at later times. In fact,
AAV vector transduction in the liver can result in the
induction of immune tolerance to the transgene product
(Mingozzi et al, 2003). This tolerance was sustained even after
a strong challenge with an adenovirus vector expressing the
identical transgene product.
The promise of animal studies using liver-directed AAV
vectors prompted a second clinical trial testing the safety and
efﬁcacy of an AAV vector for the treatment of haemophilia B
(Manno et al, 2006). In this trial, a liver-speciﬁc promoter
was used to drive expression of the F9 transgene. Vector was
infused into the hepatic artery of haemophilia B subjects at
three different doses: 8 · 10
10 vg/kg, 4 · 10
11 vg/kg and
2 · 10
12 vg/kg. At the low and intermediate doses, no Factor
IX expression was detected during the course of study. At the
highest dose tested, 1/2 subjects (subject E) experienced a rise in
Factor IX activity levels from an undetectable level at baseline to
a peak of 11Æ2% 2 weeks after vector infusion. This level of
Factor IX activity was accurately predicted by the preclinical
animal studies (Mount et al, 2002). Four weeks after vector
infusion, Factor IX activity levels remained above 10%, but at
this time AST/alanine transaminase (ALT) levels rose above
100 IU/ml from a baseline of less then 50 IU/ml. By 5 weeks
after vector infusion the Factor IX activity level declined to
6Æ1% and the AST/ALT levels increased to >200 IU/ml and
>500 IU/ml, respectively. From this peak of transaminase
activity, levels slowly declined to reach baseline 14 weeks
postinfusion. Meanwhile, Factor IX activity level also receded to
baseline undetectable levels by 10 weeks postinfusion.
This unexpected sequence of events prompted a thorough
assessment of possible causes for the loss of transgene expres-
sion. A complete workup of the subject was able to rule out any
adventitious infections (e.g. hepatitis B, CMV infection, etc).
No antibody to Factor IX protein was detectable. One possible
explanation for the loss of transgene expression was a T-cell
mediated response to the transduced cells. This phenomenon
had not been observed in any animal model of AAV transduc-
tion, but unlike the animal models, humans are frequently
exposed to wild-type AAV viruses in the context of pathogens
from very early childhood (Blacklow et al, 1968, 1971). These
exposures, because they occur in the context of helper viruses,
such as adenovirus that evoke a strong immune response, may
also evoke an immune response to AAV vector proteins that
could be reactivated by AAV vector infusion. Without serial
PBMC collection, this hypothesis was difﬁcult to test, and with
the observation conﬁned to a single subject, the chance of a
repeat occurrence of this sequence of events was unclear.
Consequently, another subject (subject G) was enrolled at
the intermediate dose (4 · 10
11 vg/kg) with a PBMC collection
protocol included to allow assessment of T cell responses to
Factor IX and to AAV. The results of this analysis convincingly
demonstrated that a T-cell response to the AAV vector capsid
protein occurred following vector administration. The sub-
ject’s T-cell responses were monitored during this time by
interferon-gamma enzyme-linked immunosorbent assay
(ELISpot), using pools of 15 amino acid peptides overlapping
by 10 amino acids that spanned the entire vector capsid
sequence and the entire F9 sequence. Although T-cell
responses to the vector capsid were undetectable at baseline,
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by the ﬁrst PBMC collection time point, 2 weeks after vector
infusion, and remained positive at each time point tested up to
12 weeks after vector infusion. Simultaneous ELISpot assays to
detect immune responses to the Factor IX protein were
consistently negative. In the 14 weeks following vector admin-
istration, subject G experienced a mild transaminitis (peak
AST and ALT levels of 67 IU/l and 105 IU/l respectively) with
a temporal course closely matched to that experienced by
subject E (Manno et al, 2006). As with the other two subjects
infused at this dose, no Factor IX activity levels >1% were
detected following infusion of the vector. These ﬁndings
strongly implicate a T cell response to AAV capsid in the loss
of Factor IX expression in the subject who transiently
expressed therapeutic levels of the transgene.
Epitope mapping using the results from the ELISpot assays
identiﬁed a nine amino acid peptide that appeared to be an
immunodominant epitope in the anti-capsid T-cell response of
subject G. This knowledge was used to generate a pentamer
reagent that enabled direct detection of the capsid-speciﬁc
CD8
+ T-cell population responding to this epitope. The
kinetics of the T-cell response in subject G were mapped with
this reagent and shown to overlap with the peak of serum
transaminases (Mingozzi et al, 2007). Two years after vector
infusion, PBMCs were isolated from subject E. No T-cell
response to AAV capsid was detectable directly ex vivo. Upon
expansion in the presence of AAV capsid peptides, however,
a single immunodominant epitope from the AAV capsid
invoked a signiﬁcant expansion of T cells from the PBMCs of
subject E. Following two rounds of PBMC expansion in the
presence of this peptide, 8Æ8% of the CD8
+ T cells in this
culture secreted interferon gamma upon re-exposure to the
epitope (Mingozzi et al, 2007). Also of note from these studies,
immune responses to AAV capsid were detectable in normal,
uninfused subjects in both PBMCs and splenocytes, suggesting
that the events seen in this trial were not aberrant and would
be repeated if additional donors were infused.
Given the likelihood that an immune response to AAV capsid
ablated the transduced cells, and that capsid is present only
transientlybeforebeingdegradedandclearedfromthecells,one
potential solution is to block the immune response to capsid
pharmacologically until capsid has been metabolized and
cleared from the cells. This raises the question of the duration
of persistence of the capsid in the transduced cell, or more
precisely, the duration of persistence of peptide-major histo-
compatibility complexes on the cell surface. Attempts to
generate an animal model that replicates these ﬁndings have
so far been unsuccessful (Li et al, 2007a,b; Wang et al, 2007).
Most approaches have relied on a prime-boost regimen with
adenoviral or plasmid vectors expressing AAV capsid, to
generatearobustCD8
+TcellresponsetoAAVcapsid.However,
when these immunized mice are challenged with an AAV vector
encoding a human F9 transgene under the control of a liver-
speciﬁc promoter (Li et al, 2007b), the transduced hepatocytes
persist even in the presence of AAV capsid-speciﬁc T-cells. In
fact, no diminution in transgene expression was detected as
compared to unimmunized mice or control immunized mice.
The next phase in gene transfer for haemophilia
Safe, long-term expression of clotting factors has been
successfully achieved in large animal models of haemophilia
using multiple gene transfer strategies, but these ﬁndings have
not yet been translated into success in patients. Ongoing and
proposed clinical studies should help to determine whether
AAV-mediated gene transfer to the liver can achieve success.
The initial liver trial is set to resume, at a dose approximately
half that used in subject E, and with the addition of transient
immunosuppression to block the T-cell response to the
capsid. If a capsid-speciﬁc T-cell response was indeed
causative in the loss of transduced hepatocytes in subject E,
an important question remains: will the immunosuppressive
regimen selected be sufﬁcient to block the response? It is also
not entirely clear how long the regimen will need to be
maintained. Alternative hypotheses to explain the ﬁndings in
the liver-directed AAV trial have been proposed. One
hypothesis suggests that fragments of the AAV capsid were
expressed in the transduced cells as a result of low-level
packaging of these sequences during the vector production
process (http://www4.od.nih.gov/oba/RAC/meeting.html).
This hypothesis does not adequately explain the difference
in ﬁndings between animal models and humans. A second
hypothesis is that an alternate open reading frame contained
within the F9 cDNA encodes an immunogenic protein
sequence, but this hypothesis also fails to explain the
difference between animals and humans (http://www4.od.-
nih.gov/oba/RAC/meeting.html). Other hypotheses focus on
differences in the sensitivity of immune responses in animals
and humans. There is some evidence that T cells in humans
may be more sensitive than T cells in non-human primates as
a result of differential expression of an immunomodulatory
lectin (Nguyen et al, 2006). Yet another possibility is that
a low level of CpG methylated DNA is packaged into the
vector during production and that humans possess more
sensitive innate immune responses to these stimuli. Finally it
has been proposed that there will be differences in capsid
processing and presentation with alternate AAV serotypes,
because of different kinetics of uncoating, differences in
intracellular trafﬁcking, or differences in antigen processing
(Vandenberghe et al, 2006). Based on strong preclinical data
in non-human primates, a proposed trial of AAV8 encoding a
F9 transgene will test this hypothesis (Nathwani et al, 2006).
This next-generation vector carries a self-complementary
expression cassette to enhance expression at lower doses and
encodes a codon-optimized transgene to improve transla-
tional efﬁciency. Will the muscle ultimately be a better target
for AAV-mediated Factor IX expression? It is clear that
Factor IX transgene expression persisted in subjects injected
with AAV vectors intramuscularly. New systemic approaches
to introduce AAV vector into skeletal muscle have since been
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result in stable expression or transient expression of the
transgene? Continuing studies should provide answers to
these questions, and ultimately a safe and effective long-term
treatment for haemophilia.
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